Department of Medicine, National Yang-Ming University, School of Medicine, No. 155 Section 2 Linong Street, Taipei, Taiwan.
Eur J Pharmacol. 2012 Nov 15;695(1-3):112-9. doi: 10.1016/j.ejphar.2012.07.054. Epub 2012 Sep 10.
Clopidogrel is not safe enough for the gastric mucosa in patients with high risk of peptic ulcer. This study aimed to explore if clopidogrel delays gastric ulcer healing and elucidate the involved mechanisms. Gastric ulcer was induced in rats and the ulcer size, mucosal epithelial cell proliferation of the ulcer margin, expression of growth factors [epidermal growth factor (EGF), basic fibroblast growth factor] and their receptors, and signal transduction pathways for cell proliferation were measured and compared between the clopidogrel-treated group and untreated controls. For the in vitro part, rat gastric mucosal epithelial cell line (RGM-1 cells) was used to establish EGF receptor over-expressed cells. Cell proliferation and molecular change under EGF treatment (10ng/ml) with and without clopidogrel (10(-6)M) were demonstrated. Ulcer size was significantly larger in the clopidogrel-treated group compared to the control and mucosal epithelial cell proliferation of the ulcer margin was significantly decreased in the clopidogrel-treated group (P<0.05). Clopidogrel (2mg and 10mg/kg/day) significantly decreased ulcer-induced gastric epithelial cell proliferation and ulcer-stimulated expressions of EGF receptor and phosphorylated extracellular signal-regulated kinase (PERK) at the ulcer margin (P<0.05). Clopidogrel (10(-6)M) also inhibited EGF-stimulated EGF receptor, PERK expression, and cell proliferation in RGM-1 cells (P<0.05), and caused much less inhibition of EGF-stimulated cell proliferation in EGF receptor over-expressed RGM-1 cells than in RGM-1 cells (22% vs. 32% reduction). In conclusion, clopidogrel delays gastric ulcer healing in rats via inhibiting gastric epithelial cell proliferation, at least by inhibition of the EGF receptor-ERK signal transduction pathway.
氯吡格雷对有消化性溃疡高危风险的患者的胃黏膜不够安全。本研究旨在探索氯吡格雷是否会延迟胃溃疡的愈合,并阐明相关机制。通过建立大鼠胃溃疡模型,检测和比较溃疡大小、溃疡边缘黏膜上皮细胞增殖、生长因子(表皮生长因子(EGF)、碱性成纤维细胞生长因子)及其受体表达和细胞增殖的信号转导通路,评估氯吡格雷对胃溃疡愈合的影响。在体外部分,使用大鼠胃黏膜上皮细胞系(RGM-1 细胞)建立 EGF 受体过表达细胞。观察 EGF(10ng/ml)刺激下有无氯吡格雷(10(-6)M)存在时细胞增殖和分子变化。结果显示,与对照组相比,氯吡格雷治疗组的溃疡面积显著增大,溃疡边缘黏膜上皮细胞增殖显著减少(P<0.05)。氯吡格雷(2mg 和 10mg/kg/天)显著降低了溃疡诱导的胃上皮细胞增殖和溃疡刺激的 EGF 受体和磷酸化细胞外信号调节激酶(PERK)在溃疡边缘的表达(P<0.05)。氯吡格雷(10(-6)M)也抑制了 RGM-1 细胞中 EGF 刺激的 EGF 受体、PERK 表达和细胞增殖(P<0.05),并且在 EGF 受体过表达的 RGM-1 细胞中,氯吡格雷对 EGF 刺激的细胞增殖的抑制作用明显小于 RGM-1 细胞(抑制率分别为 22%和 32%)。综上所述,氯吡格雷通过抑制胃上皮细胞增殖,至少通过抑制 EGF 受体-ERK 信号转导通路,延迟大鼠胃溃疡的愈合。